CG Oncology to Present at the TD Cowen 46th Annual Health Care Conference

Rhea-AI Summary

CG Oncology (NASDAQ: CGON) said its CEO Arthur Kuan and President Ambaw Bellete will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026 at 3:10 PM ET in Boston.

Investors can listen via a live audio webcast on the company website; a replay will be archived for about 90 days after the presentation.

News Market Reaction – CGON

+1.18%

1 alert

+1.18% News Effect

+$56M Valuation Impact

$4.84B Market Cap

0.0x Rel. Volume

On the day this news was published, CGON gained 1.18%, reflecting a mild positive market reaction. This price movement added approximately $56M to the company's valuation, bringing the market cap to $4.84B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Conference date: March 2, 2026 Presentation time: 3:10 pm ET Webcast archive length: approximately 90 days

3 metrics

Conference date March 2, 2026 TD Cowen 46th Annual Health Care Conference presentation

Presentation time 3:10 pm ET Scheduled start time for TD Cowen presentation

Webcast archive length approximately 90 days Duration replay will be available on Investor Relations website

Market Reality Check

Price: $56.99 Vol: Volume 730,025 vs 20-day ...

normal vol

$56.99 Last Close

Volume Volume 730,025 vs 20-day average 844,632 shares ahead of the TD Cowen presentation. normal

Technical Share price $57.63 is above the 200-day MA $36.22 and within $1 of the 52-week high $58.25.

Peers on Argus

CGON traded near its 52-week high while peers showed mixed moves: FOLD (-0.07), ...

2 Up 1 Down

CGON traded near its 52-week high while peers showed mixed moves: FOLD (-0.07), CELC (-1.73), TARS (1.99), IBRX (0.81), LQDA (-2.83). Momentum scanner flagged IBRX up 5.40%, TVTX up 1.22%, and TLX down 10.01%, indicating stock-specific rather than broad sector momentum.

Common Catalyst Only one peer, IBRX, had notable same-day news, highlighting revenue growth and expanded ANKTIVA approvals; no shared conference or sector-wide catalyst links directly to CGON’s TD Cowen appearance.

Historical Context

5 past events · Latest: Jan 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 09	Clinical timing update	Positive	+29.3%	Moved PIVOT-006 Phase 3 topline data up to 1H 2026.
Jan 06	Investor conference	Neutral	+0.8%	Announced presentation at 44th J.P. Morgan Healthcare Conference.
Dec 18	Research fellowship	Neutral	+1.7%	Launched second NMIBC research fellowship with two $50,000 grants.
Dec 05	Clinical data update	Positive	-3.7%	Reported promising BOND-003 and CORE-008 NMIBC efficacy and safety data.
Nov 26	Board change	Neutral	-1.5%	Added new director and noted BLA initiation for cretostimogene.

Pattern Detected

Positive clinical updates have previously seen strong gains, while even favorable data have occasionally met with negative price reactions, suggesting uneven sensitivity to news flow.

Recent Company History

Over the past few months, CG Oncology has moved from major clinical and regulatory milestones toward broader investor outreach. On Jan 9, 2026, accelerated timing for PIVOT‑006 Phase 3 topline data in IR NMIBC coincided with a 29.26% gain. Earlier, strong BOND‑003 and CORE‑008 data on Dec 5, 2025 saw a -3.67% move, showing that even promising data did not guarantee a positive reaction. The new TD Cowen conference appearance follows a similar investor-focused event at the J.P. Morgan conference on Jan 15, 2026.

Market Pulse Summary

This announcement highlights CG Oncology’s continued engagement with institutional investors through...

Analysis

This announcement highlights CG Oncology’s continued engagement with institutional investors through a TD Cowen conference presentation on March 2, 2026 at 3:10 pm ET, with a webcast archived for about 90 days. It follows prior investor events and major clinical updates, including accelerated PIVOT‑006 Phase 3 timing and strong NMIBC data. Investors may watch for any incremental clinical, regulatory, or commercialization commentary introduced during the presentation relative to recent filings and prior disclosures.

AI-generated analysis. Not financial advice.

IRVINE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman & Chief Executive Officer, and Ambaw Bellete, President & Chief Operating Officer, will present at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, at 3:10 pm ET. The conference is taking place at the Boston Marriott Copley Place in Boston, MA.

Interested parties may access the live audio webcast for this conference from the Investor Relations section of the company's website at www.cgoncology.com. The webcast replay will be available shortly after the conclusion of the live presentation and archived for approximately 90 days.

About CG Oncology
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgoncology.com. 

Contacts
Media
Sarah Connors
Vice President, Communications and Patient Advocacy, CG Oncology
sarah.connors@cgoncology.com 

Investor Relations
Megan Knight
Vice President, Investor Relations, CG Oncology
megan.knight@cgoncology.com 

FAQ

When will CG Oncology (CGON) present at the TD Cowen Health Care Conference?

CG Oncology will present on March 2, 2026 at 3:10 PM ET. According to the company, Arthur Kuan and Ambaw Bellete will deliver the presentation at the Boston Marriott Copley Place as scheduled.

Who from CG Oncology (CGON) will speak at the March 2, 2026 presentation?

The presenters are Arthur Kuan, CEO, and Ambaw Bellete, President & COO. According to the company, both executives will appear together at the TD Cowen conference session.

How can investors access the CG Oncology (CGON) webcast for the March 2 presentation?

Investors can access a live audio webcast via the company website Investor Relations section. According to the company, the webcast will stream live and a replay will be posted afterward.

Will the CG Oncology (CGON) presentation replay be available after March 2, 2026?

Yes, a replay will be available and archived for approximately 90 days. According to the company, the audio replay will appear shortly after the live presentation and remain accessible for about three months.

Where is the TD Cowen 46th Annual Health Care Conference taking place for CG Oncology's presentation?

The conference is at the Boston Marriott Copley Place in Boston, MA. According to the company, the CG Oncology presentation is scheduled during the conference program on March 2, 2026.